The combination treatment (5-FU + IM) also inhibited tumour growth (p < 0.001) compared to CT26 control; however, the efficacy of the chemotherapeutic drug was significantly (p < 0.01) compromised (Figure 1). The gene discussed is DDX53; the disease is neoplasm.